VBI-1501 / VBI Vaccines - LARVOL DELTA

Specificity and functional humoral immune responses induced by the VBI-1501A eVLP HCMV gB vaccine compared to the gB/MF59 vaccine. (PubMed, Hum Vaccin Immunother) - "While VBI1501A did not elicit IgG that bound to the clade-matched strain nor antibody-dependent cellular cytotoxicity responses, plasma IgG binding to cell associated gB and antibody dependent cellular phagocytosis responses were higher compared to the gB/MF59 vaccine. This study offers insight into strategies to improve on vaccine design of partially successful gB-containing HCMV vaccines."

Clinical • Journal • Cytomegalovirus Infection

VBI Vaccines Announces Pricing of $37.5 Million Public Offering (GlobeNewswire, VBI Vaccines, Inc.) - VBI intends to use the net proceeds from the offering to progress its research and development programs, which include, among other things, funding the continued clinical development of Sci-B-Vac®, including the ongoing Phase 3 clinical program in the United States, Europe and Canada; the Phase 1/2a clinical study of the therapeutic vaccine candidate, VBI-1901, for glioblastoma (GBM); the prophylactic vaccine candidate, VBI-1501, for cytomegalovirus (CMV); and the immuno-therapeutic candidate, VBI-2601, for hepatitis B. The net proceeds will also be used for general corporate purposes, including working capital and capital expenditures.

Clinical • Financing